These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 11188772

  • 1. The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis.
    Sørensen PS.
    Mult Scler; 2000 Oct; 6 Suppl 2():S14-7. PubMed ID: 11188772
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

  • 3. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 24; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 5. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 6. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y, Traboulsee A, Petkau AJ, Li D.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [Abstract] [Full Text] [Related]

  • 7. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 8. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP.
    Mult Scler; 2009 Sep 23; 15(9):1043-7. PubMed ID: 19570818
    [Abstract] [Full Text] [Related]

  • 9. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 23; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 10. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 11. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS.
    Neurol Sci; 2003 Oct 22; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [Abstract] [Full Text] [Related]

  • 12. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 22; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y.
    Arch Neurol; 2004 Oct 22; 61(10):1515-20. PubMed ID: 15477504
    [Abstract] [Full Text] [Related]

  • 14. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
    Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B.
    Mult Scler; 2000 Oct 22; 6 Suppl 2():S9-13. PubMed ID: 11188778
    [Abstract] [Full Text] [Related]

  • 15. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul 22; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 16. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P.
    Ann Neurol; 2009 Mar 22; 65(3):268-75. PubMed ID: 19334061
    [Abstract] [Full Text] [Related]

  • 17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 22; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 18. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 28; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 20. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.